H.C. Wainwright Talks Kamada's Recent Phase 2 Results

Kamada Ltd KMDA reported positive topline results from its Phase 2 biomarker study of inhaled alpha-1 [AAT-IH] for the treatment of alpha-1 antitrypsin deficiency [AATD]. H.C. Wainwright’s Andrew S. Fein maintained a Buy rating on the company, with a price target of $10.

The Phase 2 study of AAT-IH in AATD patients demonstrated “a significant increase in endothelial lining fluid (ELF) AAT antigenic level compared to the placebo group,” analyst Fein mentioned.

3 Objectives Met

Fein commented that although this was not a registrational study, the positive results achieve three important objectives for the long-run realization of value for AAT-IH.

  • Objective 1: Fein commented that the first objective accomplished was gaining “incremental proof” that AAT has efficacy in inhalation formulation.
  • Objective 2: Kamada is currently compiling responses to the EMA’s 120-day of questioning, and the Phase 2 results provide more data that can be submitted to the EMA.
  • Objective 3: Kamada is also in ongoing discussions with the FDA and the Phase 2 readout is a step closer to “solidifying a registrational trial design with an approvable clinically meaningful endpoint,” which is expected to be another key catalyst for the company’s stock, the analyst stated.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorLong IdeasReiterationAnalyst RatingsTrading IdeasAndrew S. FeinH.C. Wainwright
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!